Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON29964
NL-OMON29964
Withdrawn
Phase 4

Pharmacogenetics and epilepsy; analyse van de respons op lamotrigine - Pharmacogenetics of lamotrigine as an antiepileptic drug

Stichting Epilepsie Instellingen Nederland (SEIN)0 sites200 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsepilepsy10039911

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
epilepsy
Sponsor
Stichting Epilepsie Instellingen Nederland (SEIN)
Enrollment
200
Status
Withdrawn
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
Stichting Epilepsie Instellingen Nederland (SEIN)

Eligibility Criteria

Inclusion Criteria

  • •General inclusion criteria
  • •1\. Adult patients with cryptogenic or symptomatic localization\-related epilepsy, manifesting in generalized tonic\-clonic, complex partial and/or simple partial seizures.
  • •2\. Patients that are able to understand the written information about the study and are able to give informed consent.

Exclusion Criteria

  • •1\. Patients failing valproate due to other reasons than persisting seizures despite a maximum tolerated dose (i.e. failure due to adverse effects on a starting dose of valproate, failure due to non\-compliance etc).
  • •2\. Patients with generalized epilepsy and/or generalized absence\-seizures and /or myoclonic seizures.
  • •3\. Acute or progressive neurological disease.
  • •4\. History of psychiatric disease or substance addiction.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Withdrawn
Not Applicable
Genetic research of epilepsyconvulsionsepilepsy10029305
NL-OMON35985Academisch Medisch Centrum1,000
Completed
Not Applicable
The Genetics of epilepsyEpilepsy10039911
NL-OMON35608Academisch Medisch Centrum500
Recruiting
Not Applicable
Pharmacogenetic analysis to investigate the association between efficacy and neurotoxicity of oxaliplatin and single nucleotide polymorphismsColorectal cancer
JPRN-UMIN000002490Kyoto University Hospital133
Unknown
Not Applicable
Drug Resistant Epilepsy: Clinical and Genetic StudyEpilepsy, Drug Resistant
NCT04166305Mansoura University Hospital180
Completed
Not Applicable
Clinical pharmacology and pharmacogenetic study on the clinical response for tamoxifeBreast cancer
JPRN-UMIN000001411Saitama Medical University, Saitama International Medical Center100